The 4th Annual Gene Therapy for Rare Disorders will focus exclusively on overcoming the late-stage commercial challenges drug developers face when delivering gene therapies to market.
With approvals in a number of indications over the last year, and more rapidly approaching on the horizon, the meeting will leverage the experience from first to market pioneers, as well as unveiling the strategies
drug developers are employing to improve efficacy, safety and commercial viability.
Incorporating insights from 80+ industry-leading speakers, this conference will delve into the key regulatory, reimbursement, clinical and manufacturing hurdles that need to be overcome to realize the commercial potential of gene therapies.
Join 600+ of your colleagues to accelerate the progress of the next generation of gene therapies.
This is your comprehensive guide to define your commercial path forward in 2020.